Back to discover
Disease

Diabetic macular edema

Late-stage therapeutic development
24
Clinical trials
8
Associated genes
4
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A Phase 2, Multicenter, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Two Doses of ENN0403 in Subjects With Diabetic Macular Edema (DME)

Clinical trial2026-10-05Status changed to Completed · ClinicalTrials.gov

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Clinical trial2026-10-02Status changed to Active, not recruiting · ClinicalTrials.gov

Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection

Clinical trial2026-09-25Status changed to Completed · ClinicalTrials.gov

A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)

Clinical trial2026-09-15Status changed to Active, not recruiting · ClinicalTrials.gov

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Clinical trial2026-08-24Status changed to Completed · ClinicalTrials.gov

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
  • 10 industry developments reported.
Upcoming Milestones
Clinical Milestones13View all 13
Results posted 1
Results expected 5
Other updates 5
+5 more in the activity timeline below
Industry & Market10View all 10
+5 more in the activity timeline below
Activity timeline23

Clinical trials

15 sponsors · 5 new · 0 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Phase 3 · Active, not recruiting · EyePoint Pharmaceuticals, Inc.

Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Phase 4 · Active, not recruiting · MaryAnn Banerji

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Phase 3 · Active, not recruiting · Pfizer

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

Phase 4 · Active, not recruiting · Edward Wood, MD

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 · Active, not recruiting · Eli Lilly and Company

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

Phase 2/3 · Active, not recruiting · EyeBiotech Ltd.
Recently completed

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Phase 3 · Completed · Tanabe Pharma Corporation

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Phase 3 · Completed · Alimera Sciences

Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study

Phase 4 · Completed · Korea University Anam Hospital

A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control

Phase 3 · Completed · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes

Phase 4 · Completed · Novartis Pharmaceuticals

Associated genes

8 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

VEGFA0.61PGF0.60ANGPT20.56VEGFC0.34VEGFB0.34ANKLE10.19BABAM10.14BDKRB10.09

Disease biology

4 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Vascular endothelial growth factor A, long formvia VEGFA0.61Placenta growth factorvia PGF0.60Angiopoietin-2via ANGPT20.56Vascular endothelial growth factor Cvia VEGFC0.34
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.